Person:
ÇAKIR, FATMA BETÜL

Profile Picture
Google ScholarScopusORCIDPublons
Status
Kurumdan Ayrılmıştır.
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
FATMA BETÜL
Last Name
ÇAKIR
Name
Email Address
Birth Date

Filters

2014 - 20162
Reset filters

Settings

Type: Article × Has files: true × Author: Cakir, FATMA BETÜL ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Desmoplastic infantile ganglioglioma: Report of an unusual case with a cranial defect.
    (2014-01-01) BASARAN, RUZİYE; Cakir, FATMA BETÜL; ISIK, N; SAV, A; ELMACI, I; BAŞARAN, RUZİYE; ÇAKIR, FATMA BETÜL
  • Thumbnail Image
    PublicationOpen Access
    Ceftriaxone-induced hemolytic anemia in a child successfully managed with intravenous immunoglobulin
    (2016-03-01) Vehapoglu, AYSEL; GOKNAR, Nilufer; TUNA, Rumeysa; Cakir, FATMA BETÜL; VEHAPOĞLU TÜRKMEN, AYSEL; ÇAKIR, FATMA BETÜL
    Drug-induced hemolytic anemia is an immune-mediated phenomenon that leads to the destruction of red blood cells. Here, we present a case of life-threatening ceftriaxone-induced hemolytic anemia (CIHA) in a previously healthy 3-year-old girl. We also reviewed the literature to summarize the clinical features and treatment of hemolytic anemia. Acute hemolysis is a rare side effect of ceftriaxone therapy associated with high mortality. Our patient had a sudden loss of consciousness with macroscopic hematuria and her hemoglobin dropped from 10.2 to 2.2 g/dl over 4 hours, indicating that the patient had life-threatening hemolysis after an intravascular dose of ceftriaxone who had previously been treated with ceftriaxone in intramuscular form for six days. CIHA is associated with a positive direct antiglobulin test, revealing the presence of IgG in all cases and C3d in most cases. Our patient's direct antiglobulin test was positive for IgG (3+) and for C3d (4+). The case was managed successfully with supportive measures and intravenous immunoglobulin therapy. Ceftriaxone is used very frequently in children; an early diagnosis and proper treatment of hemolytic anemia are essential to improve the patient outcome. The pathophysiological mechanism is the same as for non-drug autoimmune hemolytic anemia. However, there is still no consensus treatment for CIHA. Intravenous immunoglobulin can be used in clinical emergencies, such as our case, or in refractory cases.